[1] [1] OBANDO-PACHECO P, JUSTICIA-GRANDE A J, RIVERO-CALLE I, et al. Respiratory syncytial virus seasonality: a global overview[J]. J Infect Dis, 2018, 217(9): 1356-1364.

[3] [3] LI Y, WANG X, BLAU D M, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis[J]. Lancet, 2022, 399(10340): 2047-2064.

[4] [4] BRANCHE A R, SAIMAN L, WALSH E E, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020[J]. Clin Infect Dis, 2022, 74(6): 1004-1011.

[5] [5] KUMAR R, MEHTA D, MISHRA N, et al. Role of host-mediated post-translational modifications (PTMs) in RNA virus pathogenesis[J]. Int J Mol Sci, 2020, 22(1): 323.

[6] [6] SANTOS A L, LINDNER A B. Protein posttranslational modifications: roles in aging and age-related disease[J]. Oxid Med Cell Longev, 2017, 2017: 5716409.

[7] [7] KARVE T M, CHEEMA A K. Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease[J]. J Amino Acids, 2011, 2011: 207691.

[8] [8] MLLER M M. Post-translational modifications of protein backbones: unique functions, mechanisms, and challenges[J]. Biochemistry, 2018, 57(2): 177-185.

[12] [12] ARDITO F, GIULIANI M, PERRONE D, et al. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)[J]. Int J Mol Med, 2017, 40(2): 271-280.

[13] [13] KECK F, ATAEY P, AMAYA M, et al. Phosphorylation of single stranded RNA virus proteins and potential for novel therapeutic strategies[J]. Viruses, 2015, 7(10): 5257-5273.

[14] [14] LIU S, CHEN S, LI X, et al. Lck/hck/fgr-mediated tyrosine phosphorylation negatively regulates TBK1 to restrain innate antiviral responses[J]. Cell Host Microbe, 2017, 21(6): 754-768. e5.

[15] [15] ASENJO A, CUESTA I, VIVO A, et al. Phosphorylation of the human respiratory syncytial virus N protein provokes a decrease in viral RNA synthesis[J]. Virus Res, 2012, 163(1): 396-400.

[16] [16] GHILDYAL R, TENG M N, TRAN K C, et al. Nuclear transport of respiratory syncytial virus matrix protein is regulated by dual phosphorylation sites[J]. Int J Mol Sci, 2022, 23(14): 7976.

[17] [17] NOH S S, SHIN H J. RSV induces activation of intracellular EGFR on the mitochondrial membrane for virus propagation[J]. Int J Mol Sci, 2023, 24(24): 17431.

[18] [18] CURRIER M G, LEE S, STOBART C C, et al. EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression[J]. PLoS Pathog, 2016, 12(5): e1005622.

[19] [19] HAGE A, RAJSBAUM R. To TRIM or not to TRIM: the balance of host-virus interactions mediated by the ubiquitin system[J]. J Gen Virol, 2019, 100(12): 1641-1662.

[20] [20] LI Q, LI H, LI Z, et al. Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue[J]. MedComm (2020), 2024, 5(12): e70016.

[21] [21] BAN J, LEE N R, LEE N J, et al. Human respiratory syncytial virus NS 1 targets TRIM25 to suppress RIG-I ubiquitination and subsequent RIG-I-mediated antiviral signaling[J]. Viruses, 2018, 10(12): 716.

[22] [22] WHELAN J N, TRAN K C, VAN ROSSUM D B, et al. Identification of respiratory syncytial virus nonstructural protein 2 residues essential for exploitation of the host ubiquitin system and inhibition of innate immune responses[J]. J Virol, 2016, 90(14): 6453-6463.

[23] [23] SCHJOLDAGER K T, NARIMATSU Y, JOSHI H J, et al. Global view of human protein glycosylation pathways and functions[J]. Nat Rev Mol Cell Biol, 2020, 21(12): 729-749.

[25] [25] LEEMANS A, BOEREN M, VAN DER GUCHT W, et al. Removal of the N-glycosylation sequon at position N116 located in p27 of the respiratory syncytial virus fusion protein elicits enhanced antibody responses after DNA immunization[J]. Viruses, 2018, 10(8): 426.

[26] [26] TRIPP R A, JONES L P, HAYNES L M, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein[J]. Nat Immunol, 2001, 2(8): 732-738.

[27] [27] GUZMAN E, TAYLOR G. Immunology of bovine respiratory syncytial virus in calves[J]. Mol Immunol, 2015, 66(1): 48-56.

[28] [28] GRAHAM B S, MODJARRAD K, MCLELLAN J S. Novel antigens for RSV vaccines[J]. Curr Opin Immunol, 2015, 35: 30-38.

[29] [29] MURRAY L A, COMBS A N, REKAPALLI P, et al. Methods for characterizing protein acetylation during viral infection[J]. Methods Enzymol, 2019, 626: 587-620.

[30] [30] HUSAIN M, CHEUNG C Y. Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membraneviaits substrate, acetylated microtubules[J]. J Virol, 2014, 88(19): 11229-11239.

[31] [31] FENG Q, SU Z, SONG S, et al. Histone deacetylase inhibitors suppress RSV infection and alleviate virus-induced airway inflammation[J]. Int J Mol Med, 2016, 38(3): 812-822.

[32] [32] JIANG H, ZHANG X, CHEN X, et al. Protein lipidation: occurrence, mechanisms, biologicalfunctions, andenabling technologies[J]. Chem Rev, 2018, 118(3): 919-988.

[33] [33] JIN J, ZHI X, WANG X, et al. Protein palmitoylation and its pathophysiological relevance[J]. J Cell Physiol, 2021, 236(5): 3220-3233.

[34] [34] CLAUDINON J, GONNORD P, BESLARD E, et al. Palmitoylation of interferon-alpha (IFN-alpha) receptor subunit IFNAR1 is required for the activation of Stat1 and Stat2 by IFN-alpha[J]. J Biol Chem, 2009, 284(36): 24328-24340.

[35] [35] BAILEY C C, ZHONG G, HUANG I C, et al. IFITM-family proteins: the cell's first line of antiviral defense[J]. Annu Rev Virol, 2014, 1: 261-283.

[36] [36] YOUNT J S, MOLTEDO B, YANG Y Y, et al. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3[J]. Nat Chem Biol, 2010, 6(8): 610-614.